Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in Novo Nordisk’s Wegovy and Ozempic has been resolved.

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) plummeted following its fourth-quarter earnings report. The stock had ...

really difficult to find pricing information for each product mobile version of Hims is hard to read all information about the types of treatments Hims offers is in the middle or bottom of the ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...

Hims & Hers stock fell by 27% as it ... the Food and Drug Administration removed semaglutide, the active ingredient in Ozempic, from its shortage list. The FDA allows for the sale of compounded ...

However, the stock gave back a lot of gains after semaglutide, the active ingredient in GLP-1 weight loss drug Ozempic, was taken off the Food & Drug Administration's shortage list. Hims & Hers ...